PMID- 37063883
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20230424
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Challenges and opportunities in analyzing and modeling peptide presentation by 
      HLA-II proteins.
PG  - 1107266
LID - 10.3389/fimmu.2023.1107266 [doi]
LID - 1107266
AB  - The human leukocyte antigen (HLA) proteins are an indispensable component of 
      adaptive immunity because of their role in presenting self and foreign peptides 
      to T cells. Further, many complex diseases are associated with genetic variation 
      in the HLA region, implying an important role for specific HLA-presented peptides 
      in the etiology of these diseases. Identifying the specific set of peptides 
      presented by an individual's HLA proteins in vivo, as a whole being referred to 
      as the immunopeptidome, has therefore gathered increasing attention for different 
      reasons. For example, identifying neoepitopes for cancer immunotherapy, vaccine 
      development against infectious pathogens, or elucidating the role of HLA in 
      autoimmunity. Despite the tremendous progress made during the last decade in 
      these areas, several questions remain unanswered. In this perspective, we 
      highlight five remaining key challenges in the analysis of peptide presentation 
      and T cell immunogenicity and discuss potential solutions to these problems. We 
      believe that addressing these questions would not only improve our understanding 
      of disease etiology but will also have a direct translational impact in terms of 
      engineering better vaccines and in developing more potent immunotherapies.
CI  - Copyright (c) 2023 ElAbd, Bacher, Tholey, Lenz and Franke.
FAU - ElAbd, Hesham
AU  - ElAbd H
AD  - Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
FAU - Bacher, Petra
AU  - Bacher P
AD  - Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
AD  - Institute of Immunology, University of Kiel, Kiel, Germany.
FAU - Tholey, Andreas
AU  - Tholey A
AD  - Proteomics & Bioanalytics, Institute for Experimental Medicine, University of 
      Kiel, Kiel, Germany.
FAU - Lenz, Tobias L
AU  - Lenz TL
AD  - Research Unit for Evolutionary Immunogenomics, Department of Biology, University 
      of Hamburg, Hamburg, Germany.
FAU - Franke, Andre
AU  - Franke A
AD  - Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230329
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptides)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - *Histocompatibility Antigens Class I
MH  - *HLA Antigens
MH  - Peptides
MH  - Histocompatibility Antigens Class II/metabolism
MH  - T-Lymphocytes
PMC - PMC10090296
OTO - NOTNLM
OT  - HLA-II & autoimmunity
OT  - TCR - T cell receptor
OT  - immunogenicitiy
OT  - immunotherapy
OT  - mass-spectrometry (MS) based immunopeptidomics
OT  - neoantigen
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/18 06:00
MHDA- 2023/04/18 06:42
PMCR- 2023/01/01
CRDT- 2023/04/17 03:35
PHST- 2022/11/24 00:00 [received]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/04/18 06:42 [medline]
PHST- 2023/04/17 03:35 [entrez]
PHST- 2023/04/18 06:00 [pubmed]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1107266 [doi]
PST - epublish
SO  - Front Immunol. 2023 Mar 29;14:1107266. doi: 10.3389/fimmu.2023.1107266. 
      eCollection 2023.